Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04987879 · ClinicalTrials.gov registry record · NA
NASH AMPK Exercise Dosing (AMPED) Trial
A NA study of NAFLD, sponsored by Milton S. Hershey Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT04987879: Recruiting NA study of NAFLD, sponsored by Milton S. Hershey Medical Center.
NCT04987879 is a NA study of NAFLD that is actively recruiting participants, run by Milton S. Hershey Medical Center. The registered enrollment target is 45 participants, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04987879, a NA study of NAFLD, is actively recruiting participants, sponsored by Milton S. Hershey Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for all with NAFLD, how to best prescribe exercise as a specific treatment remains unknown, including what dose of exercise is most effective.
Primary Outcome
Degree of liver fat change as measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF) across different doses of exercise in patients with NASH.
Conditions Studied
Interventions
- BEHAVIORAL Exercise
Study Locations (1)
Pennsylvania
- Penn State Hershey Medical Center - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2022-08-30 |
| Est. Completion | 2026-07-15 |
| Phase | NA |
What NCT04987879 shows while recruiting
NCT04987879 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 163-participant average among 26 other NAFLD trials with a reported enrollment target (72% lower).
The record links to 1 condition, with NAFLD appearing as the primary indexed condition, and to 1 intervention - of which Exercise is the first listed.
NCT04987879 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04987879 about?
NCT04987879 is a clinical study titled "NASH AMPK Exercise Dosing (AMPED) Trial". There is no known cure or regulatory agency approved drug therapy for nonalcoholic fatty liver disease (NAFLD), the leading cause of liver disease worldwide, and its progressive type, NASH. This places increased importance on using exercise to treat NAFLD. While physical activity is recommended for...
What is the current status of trial NCT04987879?
This trial is currently recruiting. It is a NA study. The enrollment target is 45 participants. The study started on 2022-08-30. Estimated completion is 2026-07-15.
What conditions does trial NCT04987879 study?
This clinical trial studies the following conditions: NAFLD.
What interventions are being tested in trial NCT04987879?
The interventions under investigation include: Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT04987879?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04987879 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NAFLD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04987879's enrollment target sits among peer trials
45 22nd of 26 higher than 5 of 26 other NAFLD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NAFLD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Reversal of Lipid-Induced Insulin Resistance
RECRUITING · NA
-
NAFLD Clinical Care Pathway
RECRUITING · NA
-
Effect of VLCD on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and NAFLD
ACTIVE NOT RECRUITING · NA
-
An Imaging-based Quantitative Biomarker Assay for NAFLD in Children
ACTIVE NOT RECRUITING · NA
-
The Impact of Low-fat and Full-fat Dairy Consumption on Glucose Homeostasis (DAIRY Study)
COMPLETED · NA
-
Healthy Liver - Healthy Brain
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI